In addition, in myeloid disorders, and particularly in MDS, mutations in several genes are adverse prognostic factors, namely alterations of ASXL1, RUNX1, EZH2, and TP53 [31,32,33]. This evidence concerns the gene ASXL1 and myelodysplastic syndrome.